Does toll-like receptor 7-mediated type I interferon signaling prevent cholestasis- and hepatotoxin-induced liver fibrosis?
TLR7 signaling activates DCs to produce type I IFN, which in turn induces antifibrogenic IL-1ra production in KCs. Thus, manipulation of the TLR7-type I IFN-IL-1ra axis may be a new therapeutic strategy for the treatment of liver fibrosis.
The data trend indicated group n-HAP experienced less sensitivity over all three measures. Only the number of days of sensitivity was statistically significant.